Hims & Hers Health, Inc. (HIMS)
Why Hims & Hers Health, Inc. (HIMS) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Hims & Hers expands into menopause care as estrogen patch demand rises
Telehealth company Hims & Hers said on Wednesday it will now offer treatment options for perimenopause and menopause via its platform, as rising U.S. demand for hormone therapy strains supplies of estrogen patches.
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) reached $29.76 at the closing of the latest trading day, reflecting a -4.03% change compared to its last close.
Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program
Expand NYSE: HIMS Hims & Hers Health Today's Change (-3.89%) $-1.21 Current Price $29.80 Key Data Points Market Cap $7.1B Day's Range $27.90 - $30.86 52wk Range $13.74 - $70.43 Volume 2.1M Avg Vol 38M Gross Margin 60.86% Hims & Hers Health (HIMS 3.89%), the consumer-focused telehealth platform, closed Tuesday at $29.76, down 4.03%. The stock declined during the regular session after Amazon (AMZN +0.63%) launched a competing GLP-1 weight-loss program, though it has still gained 39.33% in the past week.
Hims & Hers Builds Scalable Data-Driven Personalized Care Platform
HIMS is building a data-driven care platform, adding Labs and multi-cancer testing to personalize treatment via continuous monitoring insights.
Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal
Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings report.
Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock?
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Hims & Hers shares jump as FDA begins review of restricted peptide compounds
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review process that could eventually reshape the regulatory status of several wellness peptides used in compounding pharmacies. The FDA announced it will hold meetings on July 23 and 24 with its Pharmacy Compounding Advisory Committee to discuss whether multiple peptide-related bulk drug substances should be considered for possible inclusion on the 503A bulks list.
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?
Hims & Hers rolls out Benefits and taps Novo Nordisk for GLP therapies in weight-loss care as revenue grows, but margins and cash flow tighten.
Hims & Hers surges 4% as peptide policy shift unlocks growth
Shares of Hims & Hers Health moved sharply higher on Thursday, extending gains from the previous session after a significant regulatory shift signaled new opportunities in the peptide market. The stock rose about 4% to $25.28 on Thursday morning after closing up 14% on Wednesday, as investors reacted to comments from Robert F.
Hims & Hers Stock Stays Hot Amid Peptides Buzz
Hims & Hers Health Inc (NYSE:HIMS) is one of the best performing stocks on the New York Stock Exchange (NYSE) today, up 4.5% to trade at $25.52.
FDA Peptide Review, A Big Moment For Hims & Hers (Rating Upgrade)
Hims & Hers faces a pivotal regulatory moment as the FDA reconsiders compounded peptide therapies, especially GLP-1 drugs like semaglutide. A permissive FDA framework could legitimize compounded peptides, unlocking renewed growth and reversing the current revenue multiple discount for HIMS. Conversely, stricter FDA action could eliminate a key growth driver, reinforcing HIMS' high-beta exposure to regulatory risk.
